Minocycline Study in Pancreatic Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 28, 2013

Primary Completion Date

September 19, 2018

Study Completion Date

September 19, 2018

Conditions
Pancreatic Cancer
Interventions
DRUG

Minocycline

100 mg by mouth two times a day (200 mg/day).

OTHER

Placebo

Matching placebo capsules by mouth twice a day.

BEHAVIORAL

Questionnaires

Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01693523 - Minocycline Study in Pancreatic Cancer Patients | Biotech Hunter | Biotech Hunter